Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind placebo-controlled study of GSK3511294 in severe uncontrolled eosinophilic asthma
jRCT2031200411Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing GSK3511294 arm with Placebo arm (2 arms). Primary endpoint: Annualized rate of clinically significant asthma exacerbations over 52 weeks. Started Mar 2021; status: completed.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031200411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200411.